乌司奴单抗与托法替布对比肿瘤坏死因子α拮抗剂在炎症性肠病中的感染风险
基于美国商业医保2008至2019年数据,纳入新启用抗TNF、乌司奴单抗或托法替布的炎症性肠病患者,采用倾向评分加权Cox模型比较感染风险。乌司奴单抗感染风险显著低于抗TNF(HR 0.93),托法替布与抗TNF相似。
要点
- 乌司奴单抗感染风险显著低于抗TNF治疗(HR 0.93,95%CI 0.86-0.99)。
- 乌司奴单抗感染相关住院有下降趋势但未达统计学显著(HR 0.84,95%CI 0.66-1.03)。
- 托法替布与抗TNF的感染风险及感染相关住院风险相似。
核心结论
- 乌司奴单抗相比抗TNF生物制剂与感染风险降低相关,托法替布与抗TNF治疗之间未观察到差异。
研究设计与样本
- 基于美国全国商业健康保险计划2008至2019年数据,识别克罗恩病或溃疡性结肠炎患者,纳入新启用抗TNF、乌司奴单抗或托法替布治疗者,采用倾向评分加权队列的Cox比例风险模型比较感染结局。
主要发现
- 研究共纳入19096例启用抗TNF、2420例启用乌司奴单抗、305例启用托法替布的炎症性肠病患者。
- 治疗期间随访中,抗TNF组7%发生感染相关住院、44%发生感染,乌司奴单抗组分别为4%和32%,托法替布组分别为6%和41%。
- 加权Cox分析中,乌司奴单抗相比抗TNF感染风险显著降低(HR 0.93,95%CI 0.86-0.99),感染相关住院有下降趋势(HR 0.84,95%CI 0.66-1.03)。
- 托法替布与抗TNF的感染风险(HR 0.97,95%CI 0.75-1.24)及感染相关住院风险(HR 0.59,95%CI 0.27-1.05)相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The comparative safety of therapies is important to inform relative positioning within the therapeutic algorithm. Tumor necrosis factor α antagonists (anti-TNF) are associated with an increased risk of infections. Whether there is a similar increase with ustekinumab (UST) or tofacitinib has not been established. METHODS: We identified patients with Crohn's disease or ulcerative colitis from a national commercial health insurance plan in the United States between 2008 and 2019. Infectious outcomes were ascertained for patients newly initiating anti-TNF, UST, or tofacitinib therapy. Cox proportional hazards models were fit in propensity score-weighted cohorts to compare rates between patients treated with UST or tofacitinib and anti-TNF therapy. RESULTS: Our study included 19,096, 2420, and 305 patients with inflammatory bowel disease initiating anti-TNF, UST, and tofacitinib therapy, respectively. Over follow-up on-treatment, 7% and 44% of anti-TNF patients had infection-related hospitalizations and developed infections, respectively, compared with 4% and 32% of UST patients and 6% and 41% of tofacitinib patients. In the weighted Cox analysis, UST was associated with a significantly lower risk of infection (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.86-0.99) compared with anti-TNF therapy. There was a trend towards a reduction in infection-related hospitalizations (HR, 0.84; 95% CI, 0.66-1.03). The risk of infections (HR, 0.97; 95% CI, 0.75-1.24) or infection-related hospitalizations (HR, 0.59; 95% CI, 0.27-1.05) were similar between patients on tofacitinib and anti-TNF. CONCLUSIONS: UST is associated with reduced risk of infections compared to anti-TNF biologics in inflammatory bowel disease, whereas no difference was observed between tofacitinib and anti-TNF therapy.
引用
- Cheng D, Kochar BD, Cai T, et al. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2022. PMID: 35066137. doi:10.1016/j.cgh.2022.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。